Under sin PhD undersøgte Elisabeth Fuchs nye albumin-baserede lægemidler til immunterapi. Albumin er vundet frem som en lovende, ikke-immunogent lægemiddelbærende platform med lang cirkulatorisk halveringstid og naturlig ophobning i sygdomsramt væv, hvilket potentielt kan overvinde begrænsninger såsom systemisk toksicitet, der er forbundet med visse immunterapier. Dette arbejde udforsker to forskellige strategier til at udnytte albumin til immunterapi: præformulering med rekombinant albumin og binding til endogent albumin, udviklet til behandling af kræft og inflammatoriske sygdomme.

The PhD degree was completed at the Interdisciplinary Nanoscience Center (iNANO), Faculty of Natural Sciences, Aarhus University.

This summary was prepared by the PhD student.

Time: Thursday 4 December 2025 at 13.00
Place: Building 1531 Room 219 (Auditorium D), Ny Munkegade 116, 8000 Aarhus C
Title of dissertation: Albumin-Based Drug Designs for Immunotherapy
Contact information: Elisabeth Fuchs, e-mail: efuchs@inano.au.dk
Members of the assessment committee:
Professor Twan Lammers, Institute for Experimental Molecular Imaging, RWTH Aachen University, Germany
Professor Henrik Vorum, Klinisk Institut, Aalborg University Hospital, Denmark
Professor Duncan Sutherland (chair), Interdisciplinary Nanoscience Center (iNANO), Aarhus University, Denmark
Main supervisor: Associate Professor Kenneth A. Howard
Language: The PhD dissertation will be defended in English

The defense is public.
The PhD thesis is available for reading at the Graduate School of Natural Sciences/GSNS, Ny Munkegade 120, building 1521, 8000 Aarhus C.